-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) issued an announcement. Recently, Changchun Jinsai Pharmaceutical Co., Ltd. (“Jinsai Pharmaceutical”), the holding subsidiary of the company, received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the registration clinical trial application for domestically produced drugs of Jinsai Pharmaceutical GenSci161 injection was accepted. GenScI 161 injection is a new therapeutic biological product class 1 drug independently developed by Jinsai Pharmaceutical. It is a novel all-human monoclonal IgG1 bispecific antibody, intended for the treatment of pyoderma gangrenosum (PG) and cold pyrine associated periodic syndrome (CAPS).
Share
Listen to the news
Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) issued an announcement. Recently, Changchun Jinsai Pharmaceutical Co., Ltd. (“Jinsai Pharmaceutical”), the holding subsidiary of the company, received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the registration clinical trial application for domestically produced drugs of Jinsai Pharmaceutical GenSci161 injection was accepted. GenScI 161 injection is a new therapeutic biological product class 1 drug independently developed by Jinsai Pharmaceutical. It is a novel all-human monoclonal IgG1 bispecific antibody, intended for the treatment of pyoderma gangrenosum (PG) and cold pyrine associated periodic syndrome (CAPS).
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending